Porton Pharma Solutions Ltd. Stock Analysis 300363.SZ

Porton Pharma Solutions Ltd. engages in the research, development and manufacture of pharmaceutical products and active pharmaceutical ingredients. The company is headquartered in Chongqing, Chongqing and currently employs 4,359 full-time employees. The company went IPO on 2014-01-29. The small molecule API business mainly provides research, development and production services for starting materials, intermediates and APIs. The small molecule preparation business mainly provides research, development and production services such as small molecule drug preparation prescription process development and optimization, as well as co-development services. The gene cell therapy business mainly includes contract development and manufacturing organization (CDMO) platforms such as plasmids and cell therapy. The new molecule business mainly provides research, development and production services for drugs such as peptides. The firm mainly operates its businesses in the domestic and overseas markets.